For the year ending 2025-12-31, APLS made $1,003,782K in revenue. $23,593K in net income. Net profit margin of 2.35%.
| Income Statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | 1,003,782 | 781,367 | 396,591 | 75,422 |
| Cost of sales | 102,236 | 117,723 | 58,510 | 5,636 |
| Research and development | 295,854 | 327,570 | 354,387 | 387,236 |
| General and administrative | - | - | 500,815 | 277,163 |
| Selling, general and administrative | 550,265 | 501,053 | - | - |
| Total operating expenses | 948,355 | 946,346 | 913,712 | 670,035 |
| Net operating income/(loss) | 55,427 | -164,979 | -517,121 | -594,613 |
| Loss on conversion of debt | - | - | - | 32,890 |
| Loss on extinguishment of development liability | - | 1,949 | - | - |
| Interest income | 13,143 | 12,773 | 20,933 | 8,914 |
| Interest expense | 44,327 | 40,391 | 29,581 | 32,626 |
| Other expense, net | -133 | -2,170 | -727 | -288 |
| Net income/(loss) before taxes | 24,110 | -196,716 | -526,496 | -651,503 |
| Income tax expense | 1,722 | 1,162 | 2,132 | 669 |
| Net income/(loss) | 22,388 | -197,878 | -528,628 | -652,172 |
| Unrealized (loss)/gain on marketable securities | - | - | - | -1 |
| Unrealized (loss)/gain on pension plans | - | 591 | -2,618 | 1,646 |
| Unrealized gain/(loss) on pension plans | -107 | - | - | - |
| Foreign currency translation | 1,098 | -357 | -49 | -430 |
| Total other comprehensive income/(loss) | 1,205 | 234 | -2,667 | 1,215 |
| Comprehensive income/(loss), net of tax | 23,593 | -197,644 | -531,295 | -650,957 |
| Basic EPS | 0.18 | -1.6 | -4.45 | -6.15 |
| Diluted EPS | 0.2 | -1.6 | -4.45 | -6.15 |
| Basic Average Shares | 126,145,000 | 123,905,000 | 118,678,000 | 106,114,000 |
| Diluted Average Shares | 129,855,000 | 123,905,000 | 118,678,000 | 106,114,000 |
Apellis Pharmaceuticals, Inc. (APLS)
Apellis Pharmaceuticals, Inc. (APLS)